SEC Form 4 · accession 0001209191-16-092996
Anacor Pharmaceuticals, Inc. · ANAC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vincent P Ippolito
Officer — EVP & Chief Commercial Officer
Period of report
Jan 19, 2016
Accepted (ET)
Jan 21, 2016 · 9:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411158
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 19, 2016 | M | 20,000 | $19.96 | A | 90,985 | D | |
| Common StockF2 | Jan 19, 2016 | S | 1,200 | $93.9204 | D | 89,785 | D | |
| Common StockF3 | Jan 19, 2016 | S | 13,300 | $95.2867 | D | 76,485 | D | |
| Common StockF4 | Jan 19, 2016 | S | 5,300 | $95.9994 | D | 71,185 | D | |
| Common StockF5 | Jan 19, 2016 | S | 200 | $96.95 | D | 70,985 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F6 | $19.96 | Jan 19, 2016 | M | 20,000 | D | — | Mar 6, 2024 | Common Stock | 20,000 | 61,000 | D |
Explanation of responses
- F1This sale was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.68 to $94.575, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.72 to $95.63, inclusive.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.78 to $96.74, inclusive.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.84 to $97.06, inclusive.
- F6The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting each month thereafter. The Vesting Commencement Date was February 28, 2014.